A Phase 3 interventional study of AD-2281 and AD-2282 in Primary Hypercholesterolemia, sponsored by Addpharma Inc.. Completed at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-08-27.
Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Hypercholesterolemia with a site in Korea, Republic of — 6 open to participants now, 11 under way, 5 of them phase 3. Hypercholesterolemia · Korea, Republic of.
Among the 81 studies in Hypercholesterolemia with a site in Korea, Republic of, this one is the 49th largest by enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2025, is one of 35 in phase 3, and was the 69th registered.
1,180 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.
Browse Hypercholesterolemia studies →6 of the 81 studies in Hypercholesterolemia with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 19–85
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 18–100
Ahn-Gook Pharmaceuticals Co.,Ltd · Sites in Korea, Republic of
Ages 19+
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19+
Stephen Nicholls · Sites in Korea, Republic of, Australia, China and 6 more countries
Ages 18+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3 · Phase 3 36 · Phase 4 21
First in 2003; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 129 is above the median of 109 across 978 interventional studies indexed under Hypercholesterolemia.
Median enrollment 251 across the 66 interventional studies, 1,839 across the 11 observational. Of the 64 that completed or were terminated, 13 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 81 have an industry lead sponsor. The 10 most frequent:
This study is registered under Addpharma Inc., one of the names counted as Yuhan Corporation. Under that name alone:
Addpharma Inc. is the lead sponsor of 58 studies on the registry; 25 are open to participants now.
Yuhan Corporation has 7 studies filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
3 of the studies in Hypercholesterolemia with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07930507Phase 3AstraZenecaA Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients | 2027-10-11 |
| NCT05325034Stephen NichollsGuideline Oriented Approach To Lipid Lowering In Asia-Pacific | 2026-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 81 studies in Hypercholesterolemia with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safetyof co-administration of AD-2281 and AD-2282 in patients with Primary Hypercholesterolemia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AD-2281 · Drug: AD-2282
Drug: AD-2281 · Drug: Placebo of AD-2282
PO, Once daily, 8weeks
PO, Once daily, 8weeks
PO, Once daily, 8weeks
Change rate of LDL-C
Percent change (%) of LDL-C from baseline at week 8
Time frame: from baseline at 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2025 to primary completion in May 2025, 3 months.
Of 123 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 3 months is below that.
Counting every sponsor, half of 126 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.